{
    "hands_on_practices": [
        {
            "introduction": "The plasma protein cascades are potent defense systems, but their power necessitates exquisite control to prevent harm to host tissues. The complement system's alternative pathway, with its constant low-level \"tickover,\" provides a perfect example of this challenge. This exercise  asks you to identify the primary mechanism that prevents this continuous, low-grade activation from escalating into systemic inflammation, highlighting the critical importance of rapid mediator inactivation in maintaining immunological homeostasis.",
            "id": "2215918",
            "problem": "The complement system is a critical component of innate immunity. One of its activation routes, the alternative pathway, is characterized by a \"tickover\" mechanism. This process involves the slow, spontaneous hydrolysis of the central complement protein C3 into C3(H2O) in the plasma. This altered C3 molecule initiates a cascade that leads to the constant, low-level generation of the small peptide C3a. C3a is a potent anaphylatoxin, a molecule capable of inducing localized inflammatory responses by acting on various cells, such as mast cells and basophils, causing them to degranulate and release histamine.\n\nGiven that the \"tickover\" mechanism continuously produces the pro-inflammatory molecule C3a, which of the following provides the primary explanation for why a healthy individual does not experience chronic, systemic inflammation?\n\nA. Host cells rapidly internalize and degrade any C3a that binds to their surface receptors, preventing the initiation of a signaling cascade.\n\nB. The concentration of C3a produced by tickover is always below the minimum threshold required to activate its corresponding receptors on immune cells.\n\nC. Fluid-phase regulatory proteins, such as Factor H, bind directly to the newly formed C3a molecules, neutralizing them before they can interact with target cells.\n\nD. A specific plasma enzyme rapidly modifies C3a by cleaving a key amino acid residue, drastically reducing its biological activity.\n\nE. C3a is only biologically active when it forms a complex with the other major anaphylatoxin, C5a, which is not produced during simple tickover.",
            "solution": "We interpret the question: continuous, low-level generation of C3a occurs during the complement alternative pathway \"tickover.\" C3a is a potent anaphylatoxin that can induce inflammation via C3a receptor on mast cells, basophils, and other cells. The question asks for the primary physiological reason why healthy individuals do not develop chronic, systemic inflammation despite this constant production.\n\nPrinciple 1: In plasma, anaphylatoxins are tightly regulated by specific serum enzymes known as carboxypeptidases (notably carboxypeptidase N, also called the anaphylatoxin inactivator). These enzymes rapidly remove the C-terminal arginine from C3a to produce C3a-desArg, which has markedly reduced affinity and activity at the C3a receptor, thereby diminishing inflammatory signaling.\n\nPrinciple 2: Factor H is a fluid-phase regulator that controls the alternative pathway by binding to C3b (and host cell surfaces bearing sialic acid/glycosaminoglycans), promoting Factor Iâ€“mediated cleavage of C3b and destabilizing the C3 convertase. It does not neutralize C3a.\n\nPrinciple 3: Receptor internalization and degradation of ligand-receptor complexes can modulate signaling, but this is not the primary systemic safeguard preventing inflammation from circulating anaphylatoxins.\n\nPrinciple 4: While the tickover rate is low, local concentrations can rise under certain conditions, so asserting that C3a is always below activation threshold is not the general, primary explanation for the absence of systemic inflammation.\n\nPrinciple 5: C3a and C5a are independently active anaphylatoxins; C3a does not require complex formation with C5a to be biologically active.\n\nOption-by-option analysis:\n- A is not the primary mechanism; receptor internalization does not prevent initial activation and is not the canonical systemic control for circulating C3a.\n- B is incorrect as an absolute statement and not the primary mechanism; local microenvironments can exceed thresholds.\n- C is incorrect because Factor H regulates C3b, not C3a.\n- D is correct: a specific plasma enzyme, carboxypeptidase N, rapidly removes the C-terminal arginine from C3a, generating C3a-desArg with drastically reduced biological activity, which is the primary reason systemic inflammation does not result from tickover.\n- E is false; C3a acts independently and does not require complexing with C5a.\n\nTherefore, the best answer is D.",
            "answer": "$$\\boxed{D}$$"
        },
        {
            "introduction": "Understanding the principles of inflammatory regulation allows us to predict what happens when these controls fail. This practice problem  moves from conceptual understanding to quantitative modeling by examining the kinetics of the kinin system in a patient with hereditary angioedema (HAE). By applying a mass-balance model, you will calculate the dynamic accumulation of bradykinin, the key mediator of angioedema, providing a powerful example of how mathematical tools can illuminate the pathophysiology of disease.",
            "id": "4432732",
            "problem": "A patient with hereditary angioedema due to C1 esterase inhibitor (C1-INH) deficiency presents shortly after a minor trauma that activates the contact system. In plasma, bradykinin is produced from high-molecular-weight kininogen by plasma kallikrein (activated downstream of coagulation Factor XII, also known as Hageman factor) and is degraded primarily by angiotensin-converting enzyme (ACE). Assume a single well-mixed plasma compartment in which the bradykinin concentration, denoted by $C(t)$, follows a mass-balance with a constant production rate and first-order degradation. Before the event at time $t=0$, the system is at steady state with baseline production rate $p_{b}$ and baseline degradation rate constant $k_{b}$. Immediately at $t=0$, due to unchecked kallikrein activity in C1-INH deficiency and concurrent ACE inhibition, the bradykinin production rate increases by a factor of $5$ relative to baseline, and the degradation rate constant decreases by $60\\%$ relative to baseline.\n\nUse the following scientifically plausible parameters:\n- Baseline production rate $p_{b} = 0.020$ pmol L$^{-1}$ s$^{-1}$.\n- Baseline degradation rate constant $k_{b} = 0.15$ s$^{-1}$.\n\nAssume the patient was at baseline steady state just prior to $t=0$. Starting from fundamental mass-balance principles and the stated assumptions, derive the expression for $C(t)$ for $t \\geq 0$ under the post-event conditions and compute the bradykinin concentration at $t = 30$ s. Express your final numerical answer in pmol L$^{-1}$ and round to four significant figures.",
            "solution": "The problem statement will first be validated against the specified criteria.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n-   **System**: A patient with hereditary angioedema due to C1 esterase inhibitor (C1-INH) deficiency.\n-   **Compartment Model**: A single well-mixed plasma compartment.\n-   **Variable**: Bradykinin concentration is denoted by $C(t)$.\n-   **Kinetic Model**: The system follows a mass-balance equation with a constant production rate and first-order degradation. The general form is $\\frac{dC}{dt} = p - kC$, where $p$ is the production rate and $k$ is the degradation rate constant.\n-   **Baseline Conditions (for $t < 0$)**:\n    -   The system is at steady state.\n    -   Baseline production rate: $p_{b} = 0.020$ pmol L$^{-1}$ s$^{-1}$.\n    -   Baseline degradation rate constant: $k_{b} = 0.15$ s$^{-1}$.\n-   **Post-Event Conditions (for $t \\geq 0$)**:\n    -   The event occurs at $t=0$.\n    -   The post-event production rate, $p_{new}$, increases by a factor of $5$ relative to baseline: $p_{new} = 5 p_b$.\n    -   The post-event degradation rate constant, $k_{new}$, decreases by $60\\%$ relative to baseline: $k_{new} = k_b (1 - 0.60) = 0.40 k_b$.\n-   **Initial Condition**: The system is at baseline steady state just prior to $t=0$. This implies that the initial concentration at $t=0$, $C(0)$, is the steady-state concentration under baseline conditions.\n-   **Task**:\n    1.  Derive the expression for $C(t)$ for $t \\geq 0$.\n    2.  Compute the value of $C(30)$, the bradykinin concentration at $t = 30$ s.\n    3.  Round the final numerical answer to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n\n-   **Scientifically Grounded**: The problem is well-grounded in an established pathophysiological context (hereditary angioedema) and employs a standard pharmacokinetic model (first-order kinetics in a single compartment). The roles of C1-INH, kallikrein, and ACE in bradykinin metabolism are correctly identified. The parameter values are stated as scientifically plausible, and their units are consistent. The problem is scientifically sound.\n-   **Well-Posed**: The problem is formulated as a first-order linear ordinary differential equation with a clearly defined initial condition. This constitutes a well-posed initial value problem, which admits a unique and stable solution.\n-   **Objective**: The problem is stated using precise, quantitative language and avoids any subjective or ambiguous terminology.\n\nThe problem does not exhibit any of the flaws listed in the validation checklist (e.g., scientific unsoundness, incompleteness, contradiction, etc.).\n\n**Step 3: Verdict and Action**\n\nThe problem is valid. A solution will be derived.\n\n### Solution Derivation\n\nThe solution proceeds in three main parts: determining the initial condition from the baseline steady state, setting up and solving the differential equation for the post-event state, and finally, computing the required numerical value.\n\n**Part 1: Determine the Initial Condition, $C(0)$**\n\nFor $t < 0$, the system is at steady state, governed by the mass-balance equation with baseline parameters:\n$$ \\frac{dC}{dt} = p_b - k_b C(t) $$\nAt steady state, the concentration does not change with time, so $\\frac{dC}{dt} = 0$. Let $C_{ss,b}$ be the baseline steady-state concentration.\n$$ 0 = p_b - k_b C_{ss,b} $$\nSolving for $C_{ss,b}$ gives:\n$$ C_{ss,b} = \\frac{p_b}{k_b} $$\nAccording to the problem statement, the system is at this steady state just prior to $t=0$. Thus, the initial concentration for the post-event period is $C(0) = C_{ss,b}$.\nSubstituting the given values:\n$$ C(0) = \\frac{0.020 \\text{ pmol L}^{-1} \\text{ s}^{-1}}{0.15 \\text{ s}^{-1}} = \\frac{0.020}{0.15} \\text{ pmol L}^{-1} = \\frac{2}{15} \\text{ pmol L}^{-1} $$\n\n**Part 2: Derive the Expression for $C(t)$ for $t \\geq 0$**\n\nFor $t \\geq 0$, the system parameters change. The new production rate is $p_{new}$ and the new degradation rate constant is $k_{new}$:\n$$ p_{new} = 5 p_b = 5 \\times (0.020 \\text{ pmol L}^{-1} \\text{ s}^{-1}) = 0.10 \\text{ pmol L}^{-1} \\text{ s}^{-1} $$\n$$ k_{new} = 0.40 k_b = 0.40 \\times (0.15 \\text{ s}^{-1}) = 0.060 \\text{ s}^{-1} $$\nThe governing differential equation for $t \\geq 0$ is:\n$$ \\frac{dC}{dt} = p_{new} - k_{new} C(t) $$\nThis is a first-order linear non-homogeneous differential equation, which can be rearranged as:\n$$ \\frac{dC}{dt} + k_{new} C(t) = p_{new} $$\nThe general solution is the sum of the homogeneous solution, $C_h(t)$, and a particular solution, $C_p(t)$.\nThe homogeneous equation is $\\frac{dC_h}{dt} + k_{new} C_h = 0$, which has the solution $C_h(t) = A \\exp(-k_{new} t)$, where $A$ is an integration constant.\nFor the particular solution, since the forcing term $p_{new}$ is constant, we can assume a constant solution $C_p(t) = K$. Substituting into the differential equation gives $0 + k_{new} K = p_{new}$, which yields $K = \\frac{p_{new}}{k_{new}}$. This particular solution represents the new steady-state concentration, $C_{ss,new}$.\nThe general solution is:\n$$ C(t) = C_h(t) + C_p(t) = A \\exp(-k_{new} t) + \\frac{p_{new}}{k_{new}} $$\nTo find the constant $A$, we apply the initial condition $C(0) = \\frac{2}{15}$ pmol L$^{-1}$:\n$$ C(0) = A \\exp(-k_{new} \\cdot 0) + \\frac{p_{new}}{k_{new}} = A + \\frac{p_{new}}{k_{new}} $$\n$$ A = C(0) - \\frac{p_{new}}{k_{new}} = \\frac{p_b}{k_b} - \\frac{p_{new}}{k_{new}} $$\nSubstituting $A$ back into the general solution, we obtain the expression for $C(t)$ for $t \\geq 0$:\n$$ C(t) = \\frac{p_{new}}{k_{new}} + \\left( \\frac{p_b}{k_b} - \\frac{p_{new}}{k_{new}} \\right) \\exp(-k_{new} t) $$\nThis is the derived expression for the bradykinin concentration as a function of time.\n\n**Part 3: Compute the Concentration at $t = 30$ s**\n\nFirst, we calculate the values of the components in the derived expression:\n-   Initial concentration: $C(0) = \\frac{p_b}{k_b} = \\frac{2}{15}$ pmol L$^{-1}$.\n-   New steady-state concentration: $C_{ss,new} = \\frac{p_{new}}{k_{new}} = \\frac{0.10 \\text{ pmol L}^{-1} \\text{ s}^{-1}}{0.060 \\text{ s}^{-1}} = \\frac{10}{6} \\text{ pmol L}^{-1} = \\frac{5}{3}$ pmol L$^{-1}$.\n-   New rate constant: $k_{new} = 0.060$ s$^{-1}$.\n\nThe specific solution is:\n$$ C(t) = \\frac{5}{3} + \\left( \\frac{2}{15} - \\frac{5}{3} \\right) \\exp(-0.060 t) $$\n$$ C(t) = \\frac{5}{3} + \\left( \\frac{2}{15} - \\frac{25}{15} \\right) \\exp(-0.060 t) $$\n$$ C(t) = \\frac{5}{3} - \\frac{23}{15} \\exp(-0.060 t) $$\nNow, we evaluate this expression at $t = 30$ s:\n$$ C(30) = \\frac{5}{3} - \\frac{23}{15} \\exp(-0.060 \\times 30) $$\n$$ C(30) = \\frac{5}{3} - \\frac{23}{15} \\exp(-1.8) $$\nUsing a calculator for the numerical values:\n$$ \\exp(-1.8) \\approx 0.1652988882 $$\n$$ \\frac{5}{3} \\approx 1.6666666667 $$\n$$ \\frac{23}{15} \\approx 1.5333333333 $$\n$$ C(30) \\approx 1.6666666667 - 1.5333333333 \\times 0.1652988882 $$\n$$ C(30) \\approx 1.6666666667 - 0.2534433010 $$\n$$ C(30) \\approx 1.4132233657 \\text{ pmol L}^{-1} $$\nRounding the result to four significant figures as required by the problem statement gives $1.413$.",
            "answer": "$$\\boxed{1.413}$$"
        },
        {
            "introduction": "The plasma protein systems are not independent pathways but an interconnected network where activation of one can influence another. This advanced practice  explores this \"cross-talk\" by modeling a scenario where both the coagulation and kinin systems contribute to activating the complement cascade. You will derive the time course of the powerful anaphylatoxin $C5a$ resulting from these interacting inputs, offering a glimpse into the systems biology approach required to fully understand complex inflammatory processes.",
            "id": "4432744",
            "problem": "In human plasma, proteolytic cascades governing inflammation exhibit cross-talk: coagulation generates thrombin, and the contact system generates plasma kallikrein, both of which can cleave complement component $C5$ to generate the anaphylatoxin $C5a$. A minimal, scientifically grounded kinetic description uses mass-action production and first-order decay. Let $T(t)$ denote thrombin concentration and $K(t)$ denote plasma kallikrein concentration. Antithrombin (AT) and C1 inhibitor (C1-INH) impose first-order decay on $T$ and $K$, respectively, while $C5a$ is cleared by first-order processes reflecting receptor binding and enzymatic inactivation. Let $C(t)$ denote the concentration of $C5a$.\n\nAssume the following dynamical laws grounded in mass-action and first-order kinetics:\n- $T$ and $K$ decay as $ \\frac{dT}{dt} = -k_{\\mathrm{AT}}\\,T$ and $ \\frac{dK}{dt} = -k_{\\mathrm{C1}}\\,K$, where $k_{\\mathrm{AT}}$ and $k_{\\mathrm{C1}}$ are positive constants.\n- $C5a$ production is proportional to the instantaneous protease concentrations and $C5a$ clearance is first-order: $\\frac{dC}{dt} = k_T\\,T + k_K\\,K - k_{\\mathrm{deg}}\\,C$, where $k_T$, $k_K$, and $k_{\\mathrm{deg}}$ are positive constants.\n\nAt $t=0$ min, the measured concentrations are $T(0)=T_0$, $K(0)=K_0$, and $C(0)=0$. In a contact activation and tissue factor co-stimulation experiment, the parameter values are:\n- $T_0 = 10$ nM, $K_0 = 8$ nM,\n- $k_{\\mathrm{AT}} = 0.20$ min$^{-1}$, $k_{\\mathrm{C1}} = 0.15$ min$^{-1}$,\n- $k_T = 0.50$ min$^{-1}$, $k_K = 0.30$ min$^{-1}$,\n- $k_{\\mathrm{deg}} = 0.40$ min$^{-1}$.\n\nStarting from these assumptions and no additional formulas, derive an analytic expression for $C(t)$ and use it to compute the concentration of $C5a$ at $t=10$ min. Express your final concentration in nM and round your answer to four significant figures.",
            "solution": "The problem statement is first subjected to a rigorous validation process.\n\nThe givens are extracted verbatim:\n1.  **Dynamical Laws**:\n    -   $\\frac{dT}{dt} = -k_{\\mathrm{AT}}\\,T$\n    -   $\\frac{dK}{dt} = -k_{\\mathrm{C1}}\\,K$\n    -   $\\frac{dC}{dt} = k_T\\,T + k_K\\,K - k_{\\mathrm{deg}}\\,C$\n2.  **Initial Conditions** at $t=0$:\n    -   $T(0) = T_0$\n    -   $K(0) = K_0$\n    -   $C(0) = 0$\n3.  **Parameter Values**:\n    -   $T_0 = 10$ nM\n    -   $K_0 = 8$ nM\n    -   $k_{\\mathrm{AT}} = 0.20$ min$^{-1}$\n    -   $k_{\\mathrm{C1}} = 0.15$ min$^{-1}$\n    -   $k_T = 0.50$ min$^{-1}$\n    -   $k_K = 0.30$ min$^{-1}$\n    -   $k_{\\mathrm{deg}} = 0.40$ min$^{-1}$\n4.  **Task**:\n    -   Derive an analytic expression for $C(t)$.\n    -   Compute the concentration of $C5a$ at $t=10$ min.\n    -   Round the final answer to four significant figures.\n\nThe problem is deemed **valid**. It presents a system of linear first-order ordinary differential equations with specified initial conditions and constant coefficients. This constitutes a well-posed initial value problem in mathematics. The underlying model is scientifically grounded, representing a standard simplification of biochemical reaction kinetics using mass-action and first-order decay principles common in systems biology and pharmacology. The biological context is sound, and all provided parameters are physically plausible and dimensionally consistent. The problem is self-contained, objective, and free from contradictions or ambiguities.\n\nThe solution proceeds by solving the system of differential equations sequentially.\n\nFirst, we solve for the concentrations of thrombin, $T(t)$, and plasma kallikrein, $K(t)$.\nThe equation for $T(t)$ is\n$$ \\frac{dT}{dt} = -k_{\\mathrm{AT}}\\,T $$\nThis is a first-order linear homogeneous differential equation. Its solution is an exponential decay function. Integrating from $t=0$ to $t$ yields:\n$$ T(t) = T(0) \\exp(-k_{\\mathrm{AT}} t) $$\nUsing the initial condition $T(0) = T_0$, we have:\n$$ T(t) = T_0 \\exp(-k_{\\mathrm{AT}} t) $$\nSimilarly, the equation for $K(t)$ is\n$$ \\frac{dK}{dt} = -k_{\\mathrm{C1}}\\,K $$\nwith the initial condition $K(0) = K_0$. The solution is:\n$$ K(t) = K_0 \\exp(-k_{\\mathrm{C1}} t) $$\n\nNext, we solve for the concentration of $C5a$, $C(t)$. The governing equation is:\n$$ \\frac{dC}{dt} = k_T\\,T(t) + k_K\\,K(t) - k_{\\mathrm{deg}}\\,C(t) $$\nSubstituting the expressions for $T(t)$ and $K(t)$:\n$$ \\frac{dC}{dt} = k_T T_0 \\exp(-k_{\\mathrm{AT}} t) + k_K K_0 \\exp(-k_{\\mathrm{C1}} t) - k_{\\mathrm{deg}}\\,C(t) $$\nThis is a first-order linear non-homogeneous differential equation. We can write it in the standard form $y' + p(t)y = q(t)$:\n$$ \\frac{dC}{dt} + k_{\\mathrm{deg}}\\,C(t) = k_T T_0 \\exp(-k_{\\mathrm{AT}} t) + k_K K_0 \\exp(-k_{\\mathrm{C1}} t) $$\nWe solve this using the method of integrating factors. The integrating factor, $I(t)$, is:\n$$ I(t) = \\exp\\left(\\int k_{\\mathrm{deg}} dt\\right) = \\exp(k_{\\mathrm{deg}} t) $$\nMultiplying the ODE by $I(t)$ gives:\n$$ \\exp(k_{\\mathrm{deg}} t) \\frac{dC}{dt} + k_{\\mathrm{deg}} \\exp(k_{\\mathrm{deg}} t) C(t) = k_T T_0 \\exp((k_{\\mathrm{deg}} - k_{\\mathrm{AT}})t) + k_K K_0 \\exp((k_{\\mathrm{deg}} - k_{\\mathrm{C1}})t) $$\nThe left side is the derivative of the product $C(t)I(t)$:\n$$ \\frac{d}{dt}\\left( C(t) \\exp(k_{\\mathrm{deg}} t) \\right) = k_T T_0 \\exp((k_{\\mathrm{deg}} - k_{\\mathrm{AT}})t) + k_K K_0 \\exp((k_{\\mathrm{deg}} - k_{\\mathrm{C1}})t) $$\nIntegrating both sides with respect to $t$:\n$$ C(t) \\exp(k_{\\mathrm{deg}} t) = \\int \\left( k_T T_0 \\exp((k_{\\mathrm{deg}} - k_{\\mathrm{AT}})t) + k_K K_0 \\exp((k_{\\mathrm{deg}} - k_{\\mathrm{C1}})t) \\right) dt $$\nSince all rate constants are distinct ($k_{\\mathrm{deg}} \\neq k_{\\mathrm{AT}}$ and $k_{\\mathrm{deg}} \\neq k_{\\mathrm{C1}}$), the exponents are non-zero, and the integration is straightforward:\n$$ C(t) \\exp(k_{\\mathrm{deg}} t) = \\frac{k_T T_0}{k_{\\mathrm{deg}} - k_{\\mathrm{AT}}} \\exp((k_{\\mathrm{deg}} - k_{\\mathrm{AT}})t) + \\frac{k_K K_0}{k_{\\mathrm{deg}} - k_{\\mathrm{C1}}} \\exp((k_{\\mathrm{deg}} - k_{\\mathrm{C1}})t) + \\text{Const} $$\nSolving for $C(t)$:\n$$ C(t) = \\frac{k_T T_0}{k_{\\mathrm{deg}} - k_{\\mathrm{AT}}} \\exp(-k_{\\mathrm{AT}}t) + \\frac{k_K K_0}{k_{\\mathrm{deg}} - k_{\\mathrm{C1}}} \\exp(-k_{\\mathrm{C1}}t) + \\text{Const} \\cdot \\exp(-k_{\\mathrm{deg}}t) $$\nWe use the initial condition $C(0) = 0$ to determine the integration constant:\n$$ 0 = \\frac{k_T T_0}{k_{\\mathrm{deg}} - k_{\\mathrm{AT}}} + \\frac{k_K K_0}{k_{\\mathrm{deg}} - k_{\\mathrm{C1}}} + \\text{Const} $$\n$$ \\text{Const} = -\\left( \\frac{k_T T_0}{k_{\\mathrm{deg}} - k_{\\mathrm{AT}}} + \\frac{k_K K_0}{k_{\\mathrm{deg}} - k_{\\mathrm{C1}}} \\right) $$\nSubstituting the constant back into the solution for $C(t)$, we obtain the final analytical expression:\n$$ C(t) = \\frac{k_T T_0}{k_{\\mathrm{deg}} - k_{\\mathrm{AT}}} \\left( \\exp(-k_{\\mathrm{AT}}t) - \\exp(-k_{\\mathrm{deg}}t) \\right) + \\frac{k_K K_0}{k_{\\mathrm{deg}} - k_{\\mathrm{C1}}} \\left( \\exp(-k_{\\mathrm{C1}}t) - \\exp(-k_{\\mathrm{deg}}t) \\right) $$\nNow, we must compute $C(t)$ at $t=10$ min using the given parameter values:\n$T_0 = 10$, $K_0 = 8$, $k_{\\mathrm{AT}} = 0.20$, $k_{\\mathrm{C1}} = 0.15$, $k_T = 0.50$, $k_K = 0.30$, and $k_{\\mathrm{deg}} = 0.40$.\n\nFirst, calculate the constant coefficients for each term:\n$$ \\frac{k_T T_0}{k_{\\mathrm{deg}} - k_{\\mathrm{AT}}} = \\frac{0.50 \\times 10}{0.40 - 0.20} = \\frac{5}{0.20} = 25 $$\n$$ \\frac{k_K K_0}{k_{\\mathrm{deg}} - k_{\\mathrm{C1}}} = \\frac{0.30 \\times 8}{0.40 - 0.15} = \\frac{2.4}{0.25} = 9.6 $$\nThe expression for $C(t)$ becomes:\n$$ C(t) = 25 \\left( \\exp(-0.20 t) - \\exp(-0.40 t) \\right) + 9.6 \\left( \\exp(-0.15 t) - \\exp(-0.40 t) \\right) $$\nNow, substitute $t=10$:\n$$ C(10) = 25 \\left( \\exp(-0.20 \\times 10) - \\exp(-0.40 \\times 10) \\right) + 9.6 \\left( \\exp(-0.15 \\times 10) - \\exp(-0.40 \\times 10) \\right) $$\n$$ C(10) = 25 \\left( \\exp(-2) - \\exp(-4) \\right) + 9.6 \\left( \\exp(-1.5) - \\exp(-4) \\right) $$\nLet's evaluate the exponential terms:\n$\\exp(-1.5) \\approx 0.223130$\n$\\exp(-2) \\approx 0.135335$\n$\\exp(-4) \\approx 0.018316$\n\nSubstituting these values into the expression for $C(10)$:\n$$ C(10) \\approx 25 \\left( 0.135335 - 0.018316 \\right) + 9.6 \\left( 0.223130 - 0.018316 \\right) $$\n$$ C(10) \\approx 25 \\left( 0.117019 \\right) + 9.6 \\left( 0.204814 \\right) $$\n$$ C(10) \\approx 2.925475 + 1.9662144 $$\n$$ C(10) \\approx 4.8916894 $$\nThe problem requires the answer to be rounded to four significant figures.\n$$ C(10) \\approx 4.892 $$\nThe concentration of $C5a$ at $t=10$ min is approximately $4.892$ nM.",
            "answer": "$$\\boxed{4.892}$$"
        }
    ]
}